Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases

1 Li H, Fu ZY, Arslan ME, Lee H, Cho D. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Exp Med 2021; 11: 79–92. doi: 10.5493/wjem.v11.i6.79 LiH FuZY ArslanME LeeH ChoD Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: a comprehensive review World J Exp Med 2021 11 79 92 10.5493/wjem.v11.i6.79 Open DOISearch in Google Scholar

2 Hashash JG, Francis FF, Farraye FA. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol 2021; 17: 358–66. PMID: 34602898 HashashJG FrancisFF FarrayeFA Diagnosis and management of immune checkpoint inhibitor colitis Gastroenterol Hepatol 2021 17 358 66 PMID: 34602898 Search in Google Scholar

3 Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 2020; 16: 453–61. doi: 10.1200/OP.20.00002 GongZ WangY Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review JCO Oncol Pract 2020 16 453 61 10.1200/OP.20.00002 Open DOISearch in Google Scholar

4 Kelly-Goss MR, Badran YR, Dougan M. Update on immune checkpoint inhibitor enterocolitis. Curr Gastroenterol Rep 2022; 24: 171–81. doi: 10.1007/s11894-022-00852-7 Kelly-GossMR BadranYR DouganM Update on immune checkpoint inhibitor enterocolitis Curr Gastroenterol Rep 2022 24 171 81 10.1007/s11894-022-00852-7 Open DOISearch in Google Scholar

5 SERVICES USDOHAH, Health NIO, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. J Chem Soc Dalt Trans 2017. (cited 2024 Jul 15). Available at: https://www.meddra.org/ SERVICES USDOHAH, Health NIO, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 J Chem Soc Dalt Trans 2017 (cited 2024 Jul 15). Available at: https://www.meddra.org/ Search in Google Scholar

6 Ohwada S, Ishigami K, Yokoyama, Yoshihiro Kazama T, Masaki Y, Takahashi M, et al. Immune-related colitis and pancreatitis treated with infliximab. Case Reports Clin J Gastroenterol 2023; 16: 73–80. doi: 10.1007/s12328-022-01731-4 OhwadaS IshigamiK Yokoyama, Yoshihiro KazamaT MasakiY TakahashiM Immune-related colitis and pancreatitis treated with infliximab Case Reports Clin J Gastroenterol 2023 16 73 80 10.1007/s12328-022-01731-4 Open DOISearch in Google Scholar

7 Ofuji K, Hiramatsu K, Nosaka T, Naito T, Takahashi K, Matsuda H, et al. Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer. Clin J Gastroenterol 2021; 14: 1692–9. doi: 10.1007/s12328-021-01499-z OfujiK HiramatsuK NosakaT NaitoT TakahashiK MatsudaH Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer Clin J Gastroenterol 2021 14 1692 9 10.1007/s12328-021-01499-z Open DOISearch in Google Scholar

8 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714–68. doi: 10.1200/JCO.2017.77.6385 BrahmerJR LacchettiC SchneiderBJ AtkinsMB BrassilKJ CaterinoJM Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 2018 36 1714 68 10.1200/JCO.2017.77.6385 Open DOISearch in Google Scholar

9 Naito T, Nosaka T, Takahashi K, Ofuji K, Matsuda H, Ohtani M, et al. A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis. Clin J Gastroenterol 2021; 14: 1431–6. doi: 10.1007/s12328-021-01459-7 NaitoT NosakaT TakahashiK OfujiK MatsudaH OhtaniM A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis Clin J Gastroenterol 2021 14 1431 6 10.1007/s12328-021-01459-7 Open DOISearch in Google Scholar

10 Gallo A, Talerico R, Novello L, Giustiniani MC, D'Argento E, Bria E, et al. Collagenous colitis and atezolizumab therapy: an atypical case. Clin J Gastroenterol 2021; 14: 165–9. doi: 10.1007/s12328-020-01276-4 GalloA TalericoR NovelloL GiustinianiMC D'ArgentoE BriaE Collagenous colitis and atezolizumab therapy: an atypical case Clin J Gastroenterol 2021 14 165 9 10.1007/s12328-020-01276-4 Open DOISearch in Google Scholar

11 Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76. doi: 10.1056/NEJMoa050516 RutgeertsP SandbornWJ FeaganBG ReinischW OlsonA JohannsJ Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 2005 353 2462 76 10.1056/NEJMoa050516 Open DOISearch in Google Scholar

12 Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020; 8: 1–10. doi: 10.1136/jitc-2019-000451 MooradianMJ WangDY CoromilasA LumishM ChenT Giobbie-HurderA Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis J Immunother Cancer 2020 8 1 10 10.1136/jitc-2019-000451 Open DOISearch in Google Scholar

13 Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020; 123: 207–15. doi: 10.1038/s41416-020-0882-y CheungVTF GuptaT Olsson-BrownA SubramanianS SassonSC HeseltineJ Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020 123 207 15 10.1038/s41416-020-0882-y Open DOISearch in Google Scholar

14 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625–9. doi: 10.1056/NEJM198712243172603 SchroederKW TremaineWJ IlstrupDM Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 1987 317 1625 9 10.1056/NEJM198712243172603 Open DOISearch in Google Scholar

15 Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 1–28. doi: 10.1186/s40425-017-0300-z PuzanovI DiabA AbdallahK BinghamCO BrogdonC DaduR Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group J Immunother Cancer 2017 5 1 28 10.1186/s40425-017-0300-z Open DOISearch in Google Scholar

16 Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001 HaanenJ ObeidM SpainL CarbonnelF WangY RobertC Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2022 33 1217 38 10.1016/j.annonc.2022.10.001 Open DOISearch in Google Scholar

17 Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, et al. The characteristics of nivolumab-induced colitis: An evaluation of three cases and a literature review. BMC Gastroenterol 2018; 18: 1–5. doi: 10.1186/s12876-018-0864-1 YamauchiR ArakiT MitsuyamaK TokitoT IshiiH YoshiokaS The characteristics of nivolumab-induced colitis: An evaluation of three cases and a literature review BMC Gastroenterol 2018 18 1 5 10.1186/s12876-018-0864-1 Open DOISearch in Google Scholar